Tonix Pharmaceuticals Announces KOL Webinar to Discuss Positive Phase 3 Fibromyalgia Data, Sponsored by A.G.P.GlobeNewsWire • 01/25/24
Tonix Pharmaceuticals Presents Additional Data Highlighting the Favorable Tolerability and Differentiated Side Effect Profile of TNX-102 SL in Second Positive Phase 3 Clinical Trial for the Management of FibromyalgiaGlobeNewsWire • 01/09/24
Tonix Pharmaceuticals to Present at Two Upcoming Investor Conferences in January: Focus is on TNX-102 SL for the Management of Fibromyalgia Following Positive Topline Results in Second Pivotal Phase 3 TrialGlobeNewsWire • 01/03/24
Tonix Pharmaceuticals Announces Registered Direct Offering of up to $144 MillionGlobeNewsWire • 12/20/23
Tonix Pharmaceuticals Announces Highly Statistically Significant and Clinically Meaningful Topline Results in Second Positive Phase 3 Clinical Trial of TNX-102 SL for the Management of FibromyalgiaGlobeNewsWire • 12/20/23
Hope On The Horizon: Tonix Pharmaceuticals (NASDAQ:TNXP) Could Be On the Cusp of Changing Fibromyalgia Treatment Options With TNX-102 SLAccesswire • 12/14/23
Tonix Pharmaceuticals to Present at The National Academies Committee on the Current State of Research, Development, and Stockpiling of Smallpox Medical Countermeasures Public MeetingGlobeNewsWire • 12/11/23
Tonix Pharmaceuticals to Present at Two Upcoming Investor Conferences in DecemberGlobeNewsWire • 11/28/23
Tonix Pharmaceuticals Completes Clinical Stage of Phase 3 RESILIENT Study of TNX-102 SL for the Management of FibromyalgiaGlobeNewsWire • 11/15/23
Tonix Pharmaceuticals Announces Enrollment Initiated in Mass General Brigham Phase 2 Investigator-Initiated Study of TNX-1900 (Intranasal Potentiated Oxytocin) for Bone Health in Children with Autism Spectrum DisorderGlobeNewsWire • 11/13/23
Tonix Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational HighlightsGlobeNewsWire • 11/09/23
Tonix Pharmaceuticals' Vaccine Candidate, TNX-1800, Selected by NIH/NIAID Project NextGen for Inclusion in Clinical TrialsGlobeNewsWire • 11/02/23
Tonix Pharmaceuticals Announces Topline Results from Phase 2 Proof-of-Concept Study of TNX-601 ER for the Treatment of Major Depressive DisorderGlobeNewsWire • 10/31/23
Tonix Pharmaceuticals Announces New Data Involving TNX-1500 (Fc-modified dimeric anti-CD40L mAb) in Heart Xenotransplantation in Animal Models at the ACS Clinical Congress and IPITA-IXA-CTRMS Joint CongressGlobeNewsWire • 10/30/23
Tonix Pharmaceuticals expects topline results from migraine prevention study in DecemberProactive Investors • 10/26/23
Tonix Pharmaceuticals Completes Clinical Stage of Phase 2 PREVENTION Study of TNX-1900 for the Prevention of Migraine Headaches in Chronic MigraineursGlobeNewsWire • 10/26/23
Tonix Pharmaceuticals Presents Data from its Horsepox-Based Vaccine Development Platform at the World Vaccine Congress EuropeGlobeNewsWire • 10/19/23
Tonix Pharmaceuticals Announces Publication of Data in the Journal Nature Involving TNX-1500 (Fc-modified dimeric anti-CD40L mAb) for the Prevention of Rejection in Kidney Xenotransplantation in Animal ModelsGlobeNewsWire • 10/18/23
Tonix Pharmaceuticals Completes Clinical Stage of Phase 2 UPLIFT Study of TNX-601 ER for the Treatment of Major Depressive DisorderGlobeNewsWire • 10/16/23
Tonix Pharmaceuticals Announces Oral Presentation at the World Vaccine Congress EuropeGlobeNewsWire • 10/11/23
Tonix Pharmaceuticals Provides Overview of TNX-2900 Program for the Treatment of Prader-Willi Syndrome at the Foundation for Prader-Willi Research Family ConferenceGlobeNewsWire • 10/09/23
Tonix Pharmaceuticals Announces Issuance of EU Patent Covering Intranasal Potentiated Oxytocin (TNX-1900) for the Treatment of PainGlobeNewsWire • 10/04/23